MX2012007977A - Metodo para tratar condiciones neurologicas con glicocidos cardiacos. - Google Patents
Metodo para tratar condiciones neurologicas con glicocidos cardiacos.Info
- Publication number
- MX2012007977A MX2012007977A MX2012007977A MX2012007977A MX2012007977A MX 2012007977 A MX2012007977 A MX 2012007977A MX 2012007977 A MX2012007977 A MX 2012007977A MX 2012007977 A MX2012007977 A MX 2012007977A MX 2012007977 A MX2012007977 A MX 2012007977A
- Authority
- MX
- Mexico
- Prior art keywords
- treating neurological
- neurological conditions
- cardiac glycosides
- cardiac glycoside
- disease
- Prior art date
Links
- 229940097217 cardiac glycoside Drugs 0.000 title abstract 4
- 239000002368 cardiac glycoside Substances 0.000 title abstract 4
- 229930002534 steroid glycoside Natural products 0.000 title abstract 4
- 230000000926 neurological effect Effects 0.000 title abstract 2
- 150000008143 steroidal glycosides Chemical class 0.000 title 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
Abstract
Se proporciona un método para tratar una condición neurológica en un sujeto por medio de la administración de un glicósido cardíaco. La enfermedad de Alzheimer, la enfermedad de Huntington o la apoplejía son tratadas al administrar una cantidad terapéuticamente efectiva de un glicósido cardíaco a un sujeto. El glicósido cardíaco puede estar presente en una forma de dosificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29381210P | 2010-01-11 | 2010-01-11 | |
| PCT/US2011/020672 WO2011085307A1 (en) | 2010-01-11 | 2011-01-10 | Method of treating neurological conditions with cardiac glycosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012007977A true MX2012007977A (es) | 2012-08-23 |
Family
ID=44258983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007977A MX2012007977A (es) | 2010-01-11 | 2011-01-10 | Metodo para tratar condiciones neurologicas con glicocidos cardiacos. |
| MX2014006702A MX352950B (es) | 2010-01-11 | 2012-07-09 | Metodo para tratar condiciones neurologicas con glicosidos cardiacos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006702A MX352950B (es) | 2010-01-11 | 2012-07-09 | Metodo para tratar condiciones neurologicas con glicosidos cardiacos. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8481086B2 (es) |
| EP (1) | EP2523563B1 (es) |
| JP (1) | JP5917413B2 (es) |
| KR (2) | KR101811462B1 (es) |
| CN (1) | CN102834010B (es) |
| AU (4) | AU2011203933B2 (es) |
| BR (1) | BR112012017073A2 (es) |
| CA (1) | CA2786123C (es) |
| ES (1) | ES2638070T3 (es) |
| MX (2) | MX2012007977A (es) |
| RU (2) | RU2582223C2 (es) |
| WO (1) | WO2011085307A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101811462B1 (ko) | 2010-01-11 | 2018-01-25 | 피닉스 바이오테크놀러지 인코포레이티드. | 협죽도 추출물을 포함하는 신경질환 치료용 조성물 |
| US10383886B2 (en) | 2010-01-11 | 2019-08-20 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with oleandrin |
| US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| US10307450B2 (en) | 2010-01-11 | 2019-06-04 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| US20140088056A1 (en) * | 2010-09-28 | 2014-03-27 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| CA2818601C (en) * | 2010-11-22 | 2022-03-29 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of nerium species or thevetia species |
| CN104721195B (zh) * | 2013-12-20 | 2018-04-27 | 张震东 | 华蟾素在制备治疗糖尿病胰岛素抵抗的药物中的用途 |
| US9962485B2 (en) * | 2013-12-30 | 2018-05-08 | Cerner Innovation, Inc. | Automatically disassociating medical devices from patients |
| US10729735B1 (en) | 2016-09-14 | 2020-08-04 | Phoenix Biotechnology, Inc. | Method and compostitions for treating coronavirus infection |
| ES2874187T3 (es) * | 2016-09-14 | 2021-11-04 | Phoenix Biotechnology Inc | Método y composiciones para el tratamiento de una infección viral |
| US10702567B2 (en) | 2016-09-14 | 2020-07-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
| US10596186B2 (en) | 2016-09-14 | 2020-03-24 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infections |
| GB201708456D0 (en) * | 2017-05-26 | 2017-07-12 | Medical Res Council | Senolytic compounds |
| US11331291B2 (en) | 2017-09-14 | 2022-05-17 | Phoenix Biotechnology, Inc. | Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders |
| MX2020002883A (es) | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Método y composiciones para tratar la infección viral. |
| KR20200083969A (ko) * | 2017-09-14 | 2020-07-09 | 피닉스 바이오테크놀러지 인코포레이티드. | 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물 |
| EP3710015B1 (en) * | 2017-11-15 | 2024-01-17 | Université Laval | Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections |
| MX2021014579A (es) * | 2019-05-29 | 2022-01-11 | Phoenix Biotechnology Inc | Metodo y composiciones para tratar una infeccion por el virus linfotropico humano de celulas t tipo 1. |
| CN111603473B (zh) * | 2019-09-30 | 2022-11-25 | 上海和黄药业有限公司 | 一种对神经细胞损伤具有保护作用的组合物及其制剂和用途 |
| US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
| SG11202105728YA (en) | 2020-03-31 | 2021-11-29 | Phoenix Biotechnology Inc | Method and compositions for treating coronavirus infection |
| EP4295854A3 (en) | 2020-03-31 | 2024-04-03 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
| US12097234B2 (en) | 2020-05-24 | 2024-09-24 | Phoenix Biotechnology, Inc. | Extract containing oleandrin and method of production thereof |
| MX2022014731A (es) * | 2020-05-24 | 2023-02-27 | Phoenix Biotechnology Inc | Extracto que contiene oleandrina y metodo de produccion de este. |
| US20240166684A1 (en) * | 2021-03-10 | 2024-05-23 | Gerold Schmitt-Ulms | Compounds for altering levels of one or more nka alpha subunits and their use in treating prion diseases or brain diseases associated with cellular prion protein |
| CN114404425A (zh) * | 2022-01-27 | 2022-04-29 | 南京中医药大学 | 一种磷酸二酯酶的抑制剂及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
| EP1513403B1 (en) * | 2002-05-28 | 2017-02-15 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| EP1509156A2 (en) | 2002-05-28 | 2005-03-02 | Ortho-Tain, Inc. | Dental appliances and systems and methods for distributing dental appliances |
| WO2006044916A2 (en) * | 2004-10-18 | 2006-04-27 | Bionaut Pharmaceuticals, Inc. | Use of na+/ k+-atpase inhibitors and antagonists thereof |
| US7402325B2 (en) * | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| EP1928470A4 (en) | 2005-08-02 | 2010-09-15 | Bionaut Pharmaceuticals Inc | HYPOXIC INDUCIBLE FACTOR-1 MODULATORS AND RELEVANT APPLICATIONS FOR THE TREATMENT OF EYE DISEASES |
| JP4428481B2 (ja) * | 2006-01-16 | 2010-03-10 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
| RU2571687C2 (ru) | 2007-11-13 | 2015-12-20 | Феникс Байотекнолоджи Инк. | Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом |
| ES2326065B1 (es) | 2008-03-28 | 2010-07-08 | Consejo Superior De Investigaciones Cientificas (Csic) | Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple. |
| EA201001592A1 (ru) * | 2008-04-29 | 2011-08-30 | Гунвант Девичанд Освал | Гомеопатическое лекарственное средство |
| KR101811462B1 (ko) | 2010-01-11 | 2018-01-25 | 피닉스 바이오테크놀러지 인코포레이티드. | 협죽도 추출물을 포함하는 신경질환 치료용 조성물 |
| US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| TWI495307B (zh) | 2013-03-14 | 2015-08-01 | Realtek Semiconductor Corp | 訊號準位決定裝置及方法 |
-
2011
- 2011-01-10 KR KR1020127018043A patent/KR101811462B1/ko not_active Application Discontinuation
- 2011-01-10 CN CN201180005716.5A patent/CN102834010B/zh active Active
- 2011-01-10 US US12/987,693 patent/US8481086B2/en active Active
- 2011-01-10 BR BRBR112012017073-2A patent/BR112012017073A2/pt not_active Application Discontinuation
- 2011-01-10 KR KR1020167002807A patent/KR101774181B1/ko active IP Right Grant
- 2011-01-10 WO PCT/US2011/020672 patent/WO2011085307A1/en active Application Filing
- 2011-01-10 EP EP11732277.6A patent/EP2523563B1/en active Active
- 2011-01-10 RU RU2012134341/15A patent/RU2582223C2/ru active
- 2011-01-10 MX MX2012007977A patent/MX2012007977A/es active IP Right Grant
- 2011-01-10 JP JP2012548205A patent/JP5917413B2/ja active Active
- 2011-01-10 AU AU2011203933A patent/AU2011203933B2/en not_active Ceased
- 2011-01-10 CA CA2786123A patent/CA2786123C/en active Active
- 2011-01-10 ES ES11732277.6T patent/ES2638070T3/es active Active
- 2011-01-10 RU RU2016109107A patent/RU2674679C2/ru active
-
2012
- 2012-07-09 MX MX2014006702A patent/MX352950B/es unknown
-
2013
- 2013-06-04 US US13/909,613 patent/US9358293B2/en not_active Expired - Fee Related
- 2013-06-04 US US13/909,562 patent/US9220778B2/en active Active
-
2016
- 2016-01-12 AU AU2016200181A patent/AU2016200181B2/en not_active Ceased
- 2016-04-15 AU AU2016202421A patent/AU2016202421B2/en not_active Ceased
- 2016-05-02 US US15/143,973 patent/US9877979B2/en active Active
- 2016-11-25 AU AU2016262784A patent/AU2016262784B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016202421B2 (en) | Method of treating neurological conditions with cardiac glycosides | |
| MX345675B (es) | Metodo para tratar condiciones neurologicas con extracto de especie nerium o especie thevetia. | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| MX2014013858A (es) | Metodo para tratar un cancer positivo de gd2. | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| UA99953C2 (uk) | Лікування релаксином задишки, асоційованої з гострою серцевою недостатністю | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
| NZ612717A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| NZ715595A (en) | Treatment of disease with poly-n-acetyglucosamine nanofibers | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| MX2011008994A (es) | Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2. | |
| BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
| NZ629964A (en) | Method for treating inflammation | |
| EP2596787A4 (en) | NEW USE OF HESPERETIN | |
| IN2014MN01806A (es) | ||
| TW201129361A (en) | Methods for treating pain | |
| EA201170970A1 (ru) | Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом | |
| WO2013169291A3 (en) | Method for inducing udp-glucuronosyltransferase activity using pterostilbene | |
| BR112014029308A2 (pt) | um método de melhorar a função hepática |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |